These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 36217774)

  • 21. Kidney Diseases Associated With Alternative Complement Pathway Dysregulation and Potential Treatment Options.
    Sanghera P; Ghanta M; Ozay F; Ariyamuthu VK; Tanriover B
    Am J Med Sci; 2017 Dec; 354(6):533-538. PubMed ID: 29208248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models.
    Subías M; Tortajada A; Gastoldi S; Galbusera M; López-Perrote A; Lopez Lde J; González-Fernández FA; Villegas-Martínez A; Dominguez M; Llorca O; Noris M; Morgan BP; Rodríguez de Córdoba S
    J Immunol; 2014 Dec; 193(11):5567-75. PubMed ID: 25355917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration.
    Loyet KM; Deforge LE; Katschke KJ; Diehl L; Graham RR; Pao L; Sturgeon L; Lewin-Koh SC; Hollyfield JG; van Lookeren Campagne M
    Invest Ophthalmol Vis Sci; 2012 Sep; 53(10):6628-37. PubMed ID: 22930722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders.
    Michelfelder S; Parsons J; Bohlender LL; Hoernstein SNW; Niederkrüger H; Busch A; Krieghoff N; Koch J; Fode B; Schaaf A; Frischmuth T; Pohl M; Zipfel PF; Reski R; Decker EL; Häffner K
    J Am Soc Nephrol; 2017 May; 28(5):1462-1474. PubMed ID: 27932477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management.
    Schröder-Braunstein J; Kirschfink M
    Mol Immunol; 2019 Oct; 114():299-311. PubMed ID: 31421540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
    Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
    Front Immunol; 2018; 9():612. PubMed ID: 29670616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy.
    Haydock L; Garneau AP; Tremblay L; Yen HY; Gao H; Harrisson R; Isenring P
    J Mol Med (Berl); 2022 Feb; 100(2):269-284. PubMed ID: 34714369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Complement System Abnormalities in Patients with Atypical Hemolytic Uremic Syndrome and Catastrophic Antiphospholipid Syndrome].
    Demyanova KA; Kozlovskaya NL; Bobrova LA; Kozlov LV; Andina SS; Yurova VA; Kuchieva AM; Roshchupkina SV; Shilov EM
    Vestn Ross Akad Med Nauk; 2017; 72(1):42-52. PubMed ID: 29308852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complement activation in diseases presenting with thrombotic microangiopathy.
    Meri S
    Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breaking down the complement system: a review and update on novel therapies.
    Reddy YN; Siedlecki AM; Francis JM
    Curr Opin Nephrol Hypertens; 2017 Mar; 26(2):123-128. PubMed ID: 27977428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternative complement pathway assessment in patients with atypical HUS.
    Roumenina LT; Loirat C; Dragon-Durey MA; Halbwachs-Mecarelli L; Sautes-Fridman C; Fremeaux-Bacchi V
    J Immunol Methods; 2011 Feb; 365(1-2):8-26. PubMed ID: 21215749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective Binding of Heparin/Heparan Sulfate Oligosaccharides to Factor H and Factor H-Related Proteins: Therapeutic Potential for C3 Glomerulopathies.
    Loeven MA; Maciej-Hulme ML; Yanginlar C; Hubers MC; Kellenbach E; de Graaf M; van Kuppevelt TH; Wetzels J; Rabelink TJ; Smith RJH; van der Vlag J
    Front Immunol; 2021; 12():676662. PubMed ID: 34489931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolving complexity of complement-related diseases: C3 glomerulopathy and atypical haemolytic uremic syndrome.
    Cook HT
    Curr Opin Nephrol Hypertens; 2018 May; 27(3):165-170. PubMed ID: 29517501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.
    Togarsimalemath SK; Sethi SK; Duggal R; Le Quintrec M; Jha P; Daniel R; Gonnet F; Bansal S; Roumenina LT; Fremeaux-Bacchi V; Kher V; Dragon-Durey MA
    Kidney Int; 2017 Oct; 92(4):876-887. PubMed ID: 28729035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.
    Aradottir SS; Kristoffersson AC; Roumenina LT; Bjerre A; Kashioulis P; Palsson R; Karpman D
    Front Immunol; 2021; 12():690821. PubMed ID: 34177949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway.
    Barratt J; Weitz I
    Front Immunol; 2021; 12():712572. PubMed ID: 34566967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
    Michelfelder S; Fischer F; Wäldin A; Hörle KV; Pohl M; Parsons J; Reski R; Decker EL; Zipfel PF; Skerka C; Häffner K
    J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotype-phenotype correlations of low-frequency variants in the complement system in renal disease and age-related macular degeneration.
    Geerlings MJ; Volokhina EB; de Jong EK; van de Kar N; Pauper M; Hoyng CB; van den Heuvel LP; den Hollander AI
    Clin Genet; 2018 Oct; 94(3-4):330-338. PubMed ID: 29888403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complement and the prothrombotic state.
    Schmidt CQ; Schrezenmeier H; Kavanagh D
    Blood; 2022 Mar; 139(13):1954-1972. PubMed ID: 34415298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome.
    Józsi M; Reuter S; Nozal P; López-Trascasa M; Sánchez-Corral P; Prohászka Z; Uzonyi B
    Immunol Lett; 2014 Aug; 160(2):163-71. PubMed ID: 24491679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.